Chronic superficial gastritis
ICD-10 K29.3 is a used to indicate a diagnosis of chronic superficial gastritis.
Chronic superficial gastritis is characterized by persistent inflammation of the gastric mucosa, leading to symptoms such as abdominal pain, nausea, and dyspepsia. The condition primarily affects the stomach lining, which can become edematous and hyperemic. Chronic superficial gastritis may result from various etiological factors, including prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs), alcohol consumption, and chronic infections such as Helicobacter pylori. The disease progression can lead to complications such as gastric ulcers or even gastric cancer if left untreated. Diagnosis typically involves a combination of patient history, physical examination, and endoscopic evaluation with biopsy to confirm inflammation and rule out malignancy. Laboratory tests may also be performed to identify H. pylori infection. Management often includes lifestyle modifications, proton pump inhibitors, and eradication therapy for H. pylori, if present. Regular follow-up is essential to monitor symptoms and prevent complications.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
K29.3 covers chronic superficial gastritis, which may include conditions resulting from chronic H. pylori infection, NSAID use, or alcohol-related gastritis. It is characterized by persistent inflammation of the gastric mucosa without the presence of ulcers.
K29.3 should be used when there is clear documentation of chronic gastritis symptoms and findings. It should be differentiated from acute gastritis (K29.0) and other gastrointestinal conditions based on the duration of symptoms and diagnostic findings.
Documentation should include a detailed patient history, symptom description, results from endoscopic evaluations, biopsy results confirming chronic inflammation, and treatment plans. Evidence of lifestyle factors contributing to the condition should also be included.
